Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 45 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following European Parliament Vote on the EU Wine Package ESMO Call for Cancer Care Safeguards Reflected in the EU’s Health Crisis Preparedness Plan MOST POPULAR Sublobar Resection Noninferior to Lobectomy in Terms of DFS Among Patients... February 17, 2023 Mom Gives Birth and Receives a Breast Cancer Diagnosis on the... September 23, 2020 On your marks, get set… start-up! August 13, 2021 For Older Adults, Geriatric Assessment Reduces Cancer Treatment Side Effects December 15, 2021 Load more HOT NEWS 12 myths about sun safety debunked FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer Honoring Other’s Wishes How “the most advanced machine learning approach” is finding new cancer-causing...
